RavenDB and QBS Software Announce Strategic Partnership to Expand NoSQL Innovation Across UK and Europe
28.5.2025 08:50:00 CEST | Business Wire | Press Release
RavenDB, the pioneer of hybrid NoSQL document databases for modern applications, today announced a strategic partnership with QBS Software, a leading software distributor with a robust network of resellers and system integrators across the UK and Europe. This alliance is set to accelerate the adoption of RavenDB’s high-performance, developer-first data platform throughout the region.
As part of the partnership, QBS will offer RavenDB solutions through its extensive channel ecosystem, enabling more organizations to build responsive, intelligent applications powered by RavenDB’s unmatched performance, hybrid deployment model, and frictionless developer experience.
“RavenDB empowers the QBS community to build faster, smarter, and more cost-efficient applications,” said David Baruc, Chief Revenue Officer at RavenDB. “By combining a flexible document model with built-in full-text search, automatic indexing, and seamless deployment across cloud, on-prem, and edge, we eliminate the need for multiple tools and reduce infrastructure costs and overhead. It’s a modern solution built for real-time performance at scale with a strong ease of use.”
RavenDB is trusted by Fortune 500s, global ISVs, and innovative startups to manage mission-critical data without compromising speed, flexibility, or cost-efficiency. The platform’s built-in distributed architecture and zero-touch operational overhead allow teams to focus on building applications, not managing infrastructure.
For QBS Software, the partnership solidifies their reputation as a forward-looking, full spectrum software distributor with a commitment to innovation and strategic growth.
Ikramul Khaled, Group Head of Vendor Alliances at QBS Technology Group:
“RavenDB enhances the publisher portfolio for QBS Software by adding a high-performance, flexible and scalable NoSQL database solution. With RavenDB being optimised for speed and low-latency performance, especially in distributed systems and cloud environments, this gives QBS a competitive edge in offering scalable database solutions to our partners.”
As part of the go-to-market collaboration, RavenDB and QBS will jointly host educational webinars, training programs, and partner enablement sessions aimed at accelerating time-to-value for customers and resellers alike.
To learn more about the RavenDB-QBS partnership visit ravendb.net/partners.
About RavenDB
RavenDB is the hybrid NoSQL document database built for modern application development. Used by 12,000 companies across 50 industries, RavenDB helps teams move faster with seamless data management across cloud, on-prem, and edge environments. With full-text search, automatic indexes, and an easy-to-use studio for monitoring and administration, RavenDB is the database developers love and enterprises trust. Learn more at ravendb.net.
About QBS Software
QBS Software (QBS) operates the world’s largest enterprise software delivery platform, with a network of over 12,500 SaaS vendors. QBS specialises in long-tail software procurement, delivering niche and emerging software solutions. By simplifying software sourcing, procurement, and delivery, QBS empowers partners to focus on driving business growth. Visit qbssoftware.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250527583649/en/
Contacts
Media Contact
Ron Shelemay
Chief Marketing Officer
RavenDB
ron.shelemay@ravendb.net
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom